Bio-Techne Stock: Drug Pricing Deal Boosts Optimism
Update: 2025-09-30
Description
Why Bio-Techne Stock Soared (Then Stumbled): A potential drug pricing deal sent Bio-Techne shares soaring over 5%, but don't get too excited. Despite Pfizer's move to lower drug prices, Bio-Techne's volatile year continues, with cautious outlooks and market unpredictability keeping investors on edge. Is this a turning point or just another bump in the road for the life sciences company?
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
